New class of platelet blockers proves effective in phase III trial, study suggests
Monday, March 26, 2012 - 12:30
in Health & Medicine
Adding vorapaxar, an investigational platelet blocker, to standard antiplatelet therapy significantly reduces the risk of recurrent cardiovascular events in patients with known atherosclerosis, a hardening and narrowing of the arteries, according to new research.